Company news
Jupiter Neurosciences, Inc. (NASDAQ:JUNS) news
Every Jupiter Neurosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Jupiter Neurosciences, Inc. Announces Reverse Stock Split
August 5, 2026
Jupiter Neurosciences Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 Million
July 22, 2026
Jupiter Neurosciences (NASDAQ: JUNS) Signs Definitive Agreement for Exclusive U.S. Rights to ALA-002 in Transaction Valued at Up to $100 ...
July 21, 2026
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson
July 7, 2026
Jupiter Neurosciences Announces Patient Enrollment Underway in Phase 2a RESET Trial in Parkinson’s Disease
May 27, 2026
D. Boral Capital Acted as Exclusive Placement Agent to Jupiter Neurosciences, Inc. (Nasdaq:JUNS) in Connection with its ~$2 Million Regis...
May 26, 2026
Jupiter Neurosciences Announces Closing of $2.0 Million Registered Direct Offering
May 21, 2026
Jupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offering
May 20, 2026
PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neuroscie...
May 20, 2026
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Bio...
May 20, 2026
Jupiter Neurosciences, Inc. to Present at The Market Movers Investor Summit
May 4, 2026
Jupiter Neurosciences, Inc. to Present at Centri Capital Conference on April 14
April 13, 2026
Jupiter Neurosciences Appoints Kristopher Fishman and Sanjiv Lal to Nugevia™ Advisory Board
April 7, 2026
Jupiter Neurosciences to Present at Emerging Growth Conference on April 2
March 31, 2026
Jupiter Neurosciences to Present at BIO Investment and Growth Summit 2026
March 2, 2026
Jupiter Neurosciences Invited to Present Clinical and Commercial Progress at Investor Dinner at Mar-a-Lago
February 25, 2026
Jupiter Neurosciences Amends Yorkville Installment Provisions to Align Capital With Clinical and Commercial Execution
February 23, 2026
Jupiter Neurosciences Selected as B2i Digital Featured Company
February 12, 2026
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
January 28, 2026
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
January 27, 2026
Join Jupiter Neurosciences’ Exclusive Live Investor Webinar and Q&A Session on January 6
December 23, 2025
Jupiter Neurosciences Marks Transformational First Year as a Public Company, Entering 2026 with Powerful Clinical and Commercial Momentum
December 3, 2025
Jupiter Neurosciences to Participate in NobleCon21
December 2, 2025
Jupiter Neurosciences Brings Its Brain Health Expertise To The Masses With Nugevia - And A Range Of Celebs From Athletes To Scientists Ar...
November 6, 2025
Jupiter Neurosciences Receives FDA Clearance of IND Application to Initiate Phase 2a Clinical Trial of JOTROL™ in Parkinson’s Disease
November 5, 2025
Jupiter Neurosciences Enters into Agreements for up to $20 Million in Flexible Financing
October 27, 2025
Jupiter Neurosciences Names Visionary Entrepreneur and Biohacker Jean Fallacara as Third Nugevia™ Brand Ambassador
September 15, 2025
Jupiter Neurosciences Launches Nugevia™ Website and Opens Pre-Orders for Groundbreaking Longevity Supplements
August 26, 2025
Jupiter Neurosciences Names NBA Legend Chris Webber as Second Nugevia™ Brand Ambassador
August 19, 2025
Longevity In A Capsule: Jupiter Neurosciences Launches First Three Supplements Under Nugevia(TM) Brand
August 19, 2025
Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
August 11, 2025
Jupiter Neurosciences Highlights Critical Advancement of JOTROL™ Over Traditional Resveratrol with Breakthrough Bioavailability and CNS-T...
July 23, 2025
Jupiter Neurosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
July 10, 2025
Jupiter Neurosciences Showcases Nugevia™ PWR: Mitochondrial Optimization Supplement Designed to Boost Energy, Endurance, and Recovery
June 30, 2025
Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
June 27, 2025
Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
June 23, 2025
Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
June 9, 2025
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
April 8, 2025
Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
March 4, 2025
Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
February 4, 2025
Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
February 3, 2025
Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
January 30, 2025
Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
January 13, 2025